Multiple myeloma - lenalidomide and pomalidomide
The Pharmaceutical Benefits Scheme (PBS) subsidises lenalidomide and pomalidomide for patients with multiple myeloma.
Authority to provide PBS subsidised lenalidomide and pomalidomide to patients with multiple myeloma is available under Section 100 of the National Health Act 1953.
For initial treatments, the Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing lenalidomide and pomalidomide.
Contact our Complex Drugs Programs enquiry line to obtain authority to continue treatment of a patient with multiple myeloma, who does not have progressive disease, with:
- lenalidomide as monotherapy or in combination with dexamethasone, or
- pomalidomide in combination with dexamethasone
Patients must meet the relevant criteria as indicated in the restriction and be eligible for PBS subsidised medicines. Schedule item details
Schedule item details
This medicine is only available to a patient who is attending:
- an approved private hospital
- a participating public hospital or
- a public hospital
- day admitted patient
- non-admitted patient or
- a patient on discharge
Lenalidomide is available as 5 mg, 10 mg, 15 mg or 25 mg capsules in a pack size of 21. The recommended starting dose of lenalidomide is 25 mg orally once daily on days 1 to 21 of repeated 28-day cycles.
An authority prescription should be written for the strength required, a quantity of 21 capsules and up to 2 repeats.
Pomalidomide is available as 3 mg or 4 mg capsules in a pack size of 21. The recommended starting dose of pomalidomide is 4 mg/day taken orally once daily on days 1 to 21 of repeated 28-day cycles.
An authority prescription should be written for the strength required, a quantity of 21 capsules with two repeats.
Patients receiving lenalidomide or pomalidomide under the PBS listing must be registered in the i-access risk management program.
Lodging an application
All applications for authority to provide PBS subsidised lenalidomide or pomalidomide treatment for multiple myeloma must be provided in writing.
For more information contact the Complex Drugs Programs enquiry line.